Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04312997 · ClinicalTrials.gov registry record · Phase 2
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
A Phase 2 study, sponsored by Pulmotect.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT04312997 is a Phase 2 study that has completed, run by Pulmotect. The registered enrollment target is 101 participants.
The verdict
NCT04312997, a Phase 2 study, has completed, sponsored by Pulmotect.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
Adults who have tested positive for SARS-CoV-2 infection and who may require supplemental oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in addition to their normal care. Subjects will be be followed and assessed for their clinical status over 28 days to see if PUL-042 Inhalation Solution improves the clinical outcome
Interventions
- DRUG Placebo
- DRUG PUL-042 Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2021-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04312997
The ClinicalTrials.gov registry entry for NCT04312997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pulmotect, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04312997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04312997 about?
NCT04312997 is a clinical study titled "The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection". Adults who have tested positive for SARS-CoV-2 infection and who may require supplemental oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in addition to their normal care. Subjects will be be followed and assessed for their clinical status over 28 days to se...
What is the current status of trial NCT04312997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2020-06-16. Estimated completion is 2021-07-02.
What interventions are being tested in trial NCT04312997?
The interventions under investigation include: Placebo (DRUG), PUL-042 Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT04312997?
This trial is sponsored by Pulmotect, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.